These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 23562987

  • 21. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 1. TNF inhibitors].
    Amano K.
    Nihon Naika Gakkai Zasshi; 2011 Oct 10; 100(10):2966-71. PubMed ID: 22175139
    [No Abstract] [Full Text] [Related]

  • 22. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.
    Caso F, Cantarini L, Morisco F, Del Puente A, Ramonda R, Fiocco U, Lubrano E, Peluso R, Caso P, Galeazzi M, Punzi L, Scarpa R, Costa L.
    Expert Opin Biol Ther; 2015 May 10; 15(5):641-50. PubMed ID: 25652590
    [Abstract] [Full Text] [Related]

  • 23. [Biological therapies in rheumatology].
    Von Frenckell C, Malaise MG.
    Rev Med Liege; 2009 May 10; 64(5-6):293-300. PubMed ID: 19642462
    [Abstract] [Full Text] [Related]

  • 24. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B, Chen CI, Proudfoot C, Shinde S, Kuznik A, Wei W.
    Adv Ther; 2017 Nov 10; 34(11):2422-2435. PubMed ID: 29039054
    [Abstract] [Full Text] [Related]

  • 25. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.
    Kvamme MK, Lie E, Uhlig T, Moger TA, Kvien TK, Kristiansen IS.
    Rheumatology (Oxford); 2015 Jul 10; 54(7):1226-35. PubMed ID: 25573840
    [Abstract] [Full Text] [Related]

  • 26. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
    Højgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L.
    Rheumatology (Oxford); 2016 Dec 10; 55(12):2191-2199. PubMed ID: 27651526
    [Abstract] [Full Text] [Related]

  • 27. Tumor necrosis factor inhibitors in psoriasis: an update.
    Kerdel FA, Strober BE.
    Semin Cutan Med Surg; 2014 Mar 10; 33(2 Suppl 2):S31-6. PubMed ID: 24979543
    [Abstract] [Full Text] [Related]

  • 28. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
    Chastek B, Becker LK, Chen CI, Mahajan P, Curtis JR.
    J Med Econ; 2017 May 10; 20(5):464-473. PubMed ID: 28010149
    [Abstract] [Full Text] [Related]

  • 29. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF.
    Scand J Rheumatol; 2005 May 10; 34(5):353-8. PubMed ID: 16234182
    [Abstract] [Full Text] [Related]

  • 30. Anti-TNF therapy.
    Thalayasingam N, Isaacs JD.
    Best Pract Res Clin Rheumatol; 2011 Aug 10; 25(4):549-67. PubMed ID: 22137924
    [Abstract] [Full Text] [Related]

  • 31. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register.
    Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP, British Society for Rheumatology Biologics Register.
    Arthritis Res Ther; 2009 Aug 10; 11(2):R52. PubMed ID: 19356232
    [Abstract] [Full Text] [Related]

  • 32. Treatment response, drug survival and safety of anti-tumour necrosis factor α therapy in 193 patients with psoriatic arthritis: a twelve-year "real life" experience.
    Soubrier AS, Bele-Philippe P, Cortet B, Ramdane-Sebbane N, Bacle-Boutry MA, Lemeunier L, Flipo RM, Paccou J.
    Joint Bone Spine; 2015 Jan 10; 82(1):31-7. PubMed ID: 25311253
    [Abstract] [Full Text] [Related]

  • 33. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F, Anelli MG, Rinaldi A, Serafino L, Covelli M, Scioscia C, Iannone F, Lapadula G.
    Drug Dev Res; 2014 Nov 10; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [Abstract] [Full Text] [Related]

  • 34. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG, Pontikaki I, Becciolini A, Biggioggero M, Ughi N, Romano M, Crotti C, Gattinara M, Gerloni V, Marchesoni A, Meroni PL.
    Clin Rheumatol; 2017 Aug 10; 36(8):1747-1755. PubMed ID: 28597133
    [Abstract] [Full Text] [Related]

  • 35. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors.
    Kim YJ, Kim YG, Shim TS, Koo BS, Hong S, Lee CK, Yoo B.
    Rheumatology (Oxford); 2014 Aug 10; 53(8):1477-81. PubMed ID: 24681840
    [Abstract] [Full Text] [Related]

  • 36. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL, Cohen PR.
    Int J Dermatol; 2011 May 10; 50(5):619-25. PubMed ID: 21506984
    [Abstract] [Full Text] [Related]

  • 37. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
    Hellgren K, Dreyer L, Arkema EV, Glintborg B, Jacobsson LT, Kristensen LE, Feltelius N, Hetland ML, Askling J, ARTIS Study Group, For the DANBIO Study Group.
    Ann Rheum Dis; 2017 Jan 10; 76(1):105-111. PubMed ID: 27147709
    [Abstract] [Full Text] [Related]

  • 38. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA.
    Semin Arthritis Rheum; 2011 Apr 10; 40(5):398-406. PubMed ID: 20843542
    [Abstract] [Full Text] [Related]

  • 39. TNF-α antagonists beyond approved indications: stories of success and prospects for the future.
    Karampetsou MP, Liossis SN, Sfikakis PP.
    QJM; 2010 Dec 10; 103(12):917-28. PubMed ID: 20802008
    [Abstract] [Full Text] [Related]

  • 40. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.
    Saad AA, Symmons DP, Noyce PR, Ashcroft DM.
    J Rheumatol; 2008 May 10; 35(5):883-90. PubMed ID: 18381787
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.